Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade A 14.1 -4.08% -0.60
VCEL closed down 4.08 percent on Friday, September 21, 2018, on 1.8 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical VCEL trend table...

Date Alert Name Type % Chg
Sep 21 Bearish Engulfing Bearish 0.00%
Sep 21 Upper Bollinger Band Walk Strength 0.00%
Sep 21 Overbought Stochastic Strength 0.00%
Sep 21 Upper Bollinger Band Touch Strength 0.00%
Sep 20 New 52 Week Closing High Bullish -4.08%
Sep 20 Expansion Breakout Bullish Swing Setup -4.08%
Sep 20 New 52 Week High Strength -4.08%
Sep 20 Stochastic Reached Overbought Strength -4.08%
Sep 20 Upper Bollinger Band Walk Strength -4.08%
Sep 20 Above Upper BB Strength -4.08%

Older signals for VCEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VCEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.8
52 Week Low 3.3
Average Volume 974,103
200-Day Moving Average 10.2639
50-Day Moving Average 11.729
20-Day Moving Average 12.8775
10-Day Moving Average 13.275
Average True Range 0.8214
ADX 19.66
+DI 31.2451
-DI 14.9399
Chandelier Exit (Long, 3 ATRs ) 12.3358
Chandelier Exit (Short, 3 ATRs ) 13.8142
Upper Bollinger Band 14.4407
Lower Bollinger Band 11.3143
Percent B (%b) 0.89
BandWidth 24.278004
MACD Line 0.6103
MACD Signal Line 0.4761
MACD Histogram 0.1342
Fundamentals Value
Market Cap 462.8 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -13.56
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.84
Resistance 3 (R3) 15.87 15.31 15.55
Resistance 2 (R2) 15.31 14.87 15.30 15.45
Resistance 1 (R1) 14.71 14.60 14.43 14.68 15.36
Pivot Point 14.15 14.15 14.02 14.14 14.15
Support 1 (S1) 13.55 13.71 13.27 13.52 12.84
Support 2 (S2) 12.99 13.44 12.98 12.75
Support 3 (S3) 12.39 12.99 12.65
Support 4 (S4) 12.36